Bioxytran (BIXT) Share-based Compensation Growth (5y) (2016 - 2026)
Bioxytran (BIXT) Share-based Compensation Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.92% |
| Dec 31, 2025 | -2.88% |
| Sep 30, 2025 | 39.19% |
| Jun 30, 2025 | -19.06% |
| Mar 31, 2025 | 21.75% |
| Dec 31, 2024 | -8.13% |
| Sep 30, 2024 | -3.39% |
| Jun 30, 2024 | 17.76% |
| Mar 31, 2024 | 75.92% |
| Dec 31, 2021 | -19.61% |
| Sep 30, 2021 | -65.18% |
| Jun 30, 2021 | -14.34% |
| Mar 31, 2021 | 14.19% |
| Dec 31, 2019 | -24.67% |
| Sep 30, 2019 | -60.58% |
| Dec 31, 2016 | -15.65% |
| Sep 30, 2016 | -30.61% |
| Jun 30, 2016 | 16.65% |
| Mar 31, 2016 | -21.82% |